Published in Br J Cancer on February 17, 2009
Comparative proteomics of colon cancer stem cells and differentiated tumor cells identifies BIRC6 as a potential therapeutic target. Mol Cell Proteomics (2011) 1.14
An investigation into the cytotoxic effects of 13-acetoxysarcocrassolide from the soft coral Sarcophyton crassocaule on bladder cancer cells. Mar Drugs (2011) 0.97
Role of Apollon in human melanoma resistance to antitumor agents that activate the intrinsic or the extrinsic apoptosis pathways. Clin Cancer Res (2012) 0.90
Ubiquitin-like (UBX)-domain-containing protein, UBXN2A, promotes cell death by interfering with the p53-Mortalin interactions in colon cancer cells. Cell Death Dis (2014) 0.86
ATP synthase subunit alpha and LV mass in ischaemic human hearts. J Cell Mol Med (2014) 0.84
BIRC6 protein, an inhibitor of apoptosis: role in survival of human prostate cancer cells. PLoS One (2013) 0.83
Apollon modulates chemosensitivity in human esophageal squamous cell carcinoma. Oncotarget (2014) 0.82
BIRC6 (APOLLON) is down-regulated in acute myeloid leukemia and its knockdown attenuates neutrophil differentiation. Exp Hematol Oncol (2012) 0.80
Knockdown of the Inhibitor of Apoptosis BRUCE Sensitizes Resistant Breast Cancer Cells to Chemotherapeutic Agents. J Cancer Sci Ther (2015) 0.75
Overexpression of BIRC6 Is a Predictor of Prognosis for Colorectal Cancer. PLoS One (2015) 0.75
miR-342 overexpression results in a synthetic lethal phenotype in BRCA1-mutant HCC1937 breast cancer cells. Oncotarget (2016) 0.75
Expression and clinical significance of Apollon in esophageal squamous cell carcinoma. Mol Med Rep (2016) 0.75
Expression and clinical significance of Apollon in renal carcinoma. Oncol Lett (2016) 0.75
Inducing death in tumor cells: roles of the inhibitor of apoptosis proteins. F1000Res (2017) 0.75
Caspase-3 is required for DNA fragmentation and morphological changes associated with apoptosis. J Biol Chem (1998) 6.84
The ubiquitin ligase COP1 is a critical negative regulator of p53. Nature (2004) 5.05
Pirh2, a p53-induced ubiquitin-protein ligase, promotes p53 degradation. Cell (2003) 4.96
A matter of life and death. Cancer Cell (2002) 4.07
IAPs: what's in a name? Mol Cell (2008) 3.66
Apollon ubiquitinates SMAC and caspase-9, and has an essential cytoprotection function. Nat Cell Biol (2004) 2.63
Coexistence of high levels of apoptotic signaling and inhibitor of apoptosis proteins in human tumor cells: implication for cancer specific therapy. Cancer Res (2003) 2.09
Dual role of BRUCE as an antiapoptotic IAP and a chimeric E2/E3 ubiquitin ligase. Mol Cell (2004) 1.73
A human IAP-family gene, apollon, expressed in human brain cancer cells. Biochem Biophys Res Commun (1999) 1.56
Nrdp1-mediated degradation of the gigantic IAP, BRUCE, is a novel pathway for triggering apoptosis. EMBO J (2004) 1.46
The p53-binding protein MDM2 gene is differentially expressed in human breast carcinoma. Cancer Res (1993) 1.45
The Birc6 (Bruce) gene regulates p53 and the mitochondrial pathway of apoptosis and is essential for mouse embryonic development. Proc Natl Acad Sci U S A (2005) 1.44
Granzyme B mimics apical caspases. Description of a unified pathway for trans-activation of executioner caspase-3 and -7. J Biol Chem (1998) 1.34
The membrane-associated inhibitor of apoptosis protein, BRUCE/Apollon, antagonizes both the precursor and mature forms of Smac and caspase-9. J Biol Chem (2004) 1.21
Targeting the FLICE Inhibitory Protein (FLIP) in cancer therapy. Mol Interv (2003) 1.19
Oncolytic adenovirus-mediated shRNA against Apollon inhibits tumor cell growth and enhances antitumor effect of 5-fluorouracil. Gene Ther (2008) 1.08
Molecular mechanisms of death-receptor-mediated apoptosis. Chembiochem (2001) 1.05
Overexpression of Apollon, an antiapoptotic protein, is associated with poor prognosis in childhood de novo acute myeloid leukemia. Clin Cancer Res (2007) 1.03
A new method for determining the status of p53 in tumor cell lines of different origin. Oncol Res (2003) 1.03
Tumors acquire inhibitor of apoptosis protein (IAP)-mediated apoptosis resistance through altered specificity of cytosolic proteolysis. J Exp Med (2003) 0.91
Induction and alternative splicing of the Bax gene mediated by p53 in a transformed endothelial cell line. Apoptosis (1999) 0.80
The Bcl-2 protein: a prognostic indicator strongly related to p53 protein in lymph node-negative breast cancer patients. J Natl Cancer Inst (1994) 2.06
Expression of the anti-apoptotic gene survivin correlates with taxol resistance in human ovarian cancer. Cell Mol Life Sci (2002) 1.65
Expression of p53, glutathione S-transferase-pi, and Bcl-2 proteins and benefit from adjuvant radiotherapy in breast cancer. J Natl Cancer Inst (1997) 1.60
Quality control for biomarker determination in oncology: the experience of the Italian Network for Quality Assessment of Tumor Biomarkers (INQAT). Int J Biol Markers (2002) 1.40
p53 as an independent prognostic marker in lymph node-negative breast cancer patients. J Natl Cancer Inst (1993) 1.39
Potentials of cell kinetics in the management of patients with ovarian cancers. Eur J Cancer (1992) 1.39
Breast cancer metastases are molecularly distinct from their primary tumors. Oncogene (2007) 1.28
Biologic and clinicopathologic factors as indicators of specific relapse types in node-negative breast cancer. J Clin Oncol (1995) 1.27
Sunitinib in advanced alveolar soft part sarcoma: evidence of a direct antitumor effect. Ann Oncol (2011) 1.24
Cell kinetics as a prognostic marker in node-negative breast cancer. Cancer (1985) 1.18
Prognostic implication of labeling index versus estrogen receptors and tumor size in node-negative breast cancer. Breast Cancer Res Treat (1986) 1.18
A gene expression signature classifying telomerase and ALT immortalization reveals an hTERT regulatory network and suggests a mesenchymal stem cell origin for ALT. Oncogene (2009) 1.14
Association between [18F]fluorodeoxyglucose uptake and postoperative histopathology, hormone receptor status, thymidine labelling index and p53 in primary breast cancer: a preliminary observation. Eur J Nucl Med (1998) 1.11
Cloning and characterization of a senescence inducing and class II tumor suppressor gene in ovarian carcinoma at chromosome region 6q27. Oncogene (2001) 1.11
Relationship between proliferative activity and estrogen receptors in breast cancer. Cancer (1979) 1.09
p53 and bcl-2 expression correlates with clinical outcome in a series of node-positive breast cancer patients. J Clin Oncol (1996) 1.09
A model of study for human cancer: Spontaneous occurring tumors in dogs. Biological features and translation for new anticancer therapies. Crit Rev Oncol Hematol (2013) 1.05
miR-205 regulates basement membrane deposition in human prostate: implications for cancer development. Cell Death Differ (2012) 1.05
Overexpression of protein kinase C epsilon is oncogenic in rat colonic epithelial cells. Oncogene (1996) 1.00
High level of telomerase RNA gene expression is associated with chromatin modification, the ALT phenotype and poor prognosis in liposarcoma. Br J Cancer (2008) 0.98
Camptothecin resistance in cancer: insights into the molecular mechanisms of a DNA-damaging drug. Curr Med Chem (2013) 0.97
Infiltrating ductal and lobular breast carcinomas are characterised by different interrelationships among markers related to angiogenesis and hormone dependence. Br J Cancer (2002) 0.96
Adjuvant CMF for node-negative and estrogen receptor-negative breast cancer patients. J Natl Cancer Inst Monogr (1992) 0.94
Inhibition of telomerase activity by a distamycin derivative: effects on cell proliferation and induction of apoptosis in human cancer cells. Eur J Cancer (2002) 0.92
Cell kinetics as a prognostic indicator in node-negative breast cancer. Eur J Cancer Clin Oncol (1989) 0.91
Dacarbazine in solitary fibrous tumor: a case series analysis and preclinical evidence vis-a-vis temozolomide and antiangiogenics. Clin Cancer Res (2013) 0.91
Heterogeneous radiation and heat sensitivity in vitro of human melanoma xenograft lines established from different lesions in the same patient. Comparisons with the radiation and heat sensitivity of cells isolated from the donor patient's surgical specimens. Int J Radiat Biol (1990) 0.90
In vitro effect of lonidamine on the cytotoxicity of mitomycin C and BCNU in human colon adenocarcinoma cells. Eur J Cancer (1994) 0.90
Time-dependent relevance of steroid receptors in breast cancer. J Clin Oncol (2000) 0.89
Estimation of differential in vitro sensitivity of non-Hodgkin lymphomas to anticancer drugs. Eur J Cancer (1981) 0.89
Possible regulation of telomerase activity by transcription and alternative splicing of telomerase reverse transcriptase in human melanoma. J Invest Dermatol (2001) 0.88
Oligomer-mediated modulation of hTERT alternative splicing induces telomerase inhibition and cell growth decline in human prostate cancer cells. Cell Mol Life Sci (2004) 0.88
Hyaluronic acid as drug delivery for sodium butyrate: improvement of the anti-proliferative activity on a breast-cancer cell line. Int J Cancer (1999) 0.88
Sodium butyrate modulates cell cycle-related proteins in HT29 human colonic adenocarcinoma cells. Cell Prolif (2000) 0.88
Inactivation of Ret/Ptc1 oncoprotein and inhibition of papillary thyroid carcinoma cell proliferation by indolinone RPI-1. Cell Mol Life Sci (2003) 0.87
Expression of P-glycoprotein and in vitro or in vivo resistance to doxorubicin and cisplatin in breast and ovarian cancers. Eur J Cancer (1994) 0.87
Validation of p53 accumulation as a predictor of distant metastasis at 10 years of follow-up in 1400 node-negative breast cancers. Clin Cancer Res (1996) 0.87
Namitecan: a hydrophilic camptothecin with a promising preclinical profile. Curr Med Chem (2012) 0.86
int-2 oncogene amplification and prognosis in node-negative breast carcinoma. Int J Cancer (1997) 0.86
Contribution of vascular endothelial growth factor to the Nottingham prognostic index in node-negative breast cancer. Br J Cancer (2001) 0.86
Hypoxia and estrogen receptor profile influence the responsiveness of human breast cancer cells to estradiol and antiestrogens. Cell Mol Life Sci (2004) 0.86
Antitumor efficacy of the heparanase inhibitor SST0001 alone and in combination with antiangiogenic agents in the treatment of human pediatric sarcoma models. Biochem Pharmacol (2013) 0.86
Synthesis and antiproliferative activity of substituted 3[2-(1H-indol-3-yl)- 1,3-thiazol-4-yl]-1H-pyrrolo[3,2-b]pyridines, marine alkaloid nortopsentin analogues. Curr Med Chem (2014) 0.86
A guide for reviewing submitted manuscripts (and indications for the design of translational research studies on biomarkers) Int J Biol Markers (1999) 0.86
Immunoreactivity to MIB-1 in breast cancer: methodological assessment and comparison with other proliferation indices. Cell Prolif (1997) 0.85
Re: Levels of hypoxia-inducible factor-1alpha during breast carcinogenesis. J Natl Cancer Inst (2001) 0.85
3H-thymidine-labeling index as a prognostic indicator in node-positive breast cancer. J Clin Oncol (1990) 0.84
Improved apoptotic cell death in drug-resistant non-small-cell lung cancer cells by tumor necrosis factor-related apoptosis-inducing ligand-based treatment. J Pharmacol Exp Ther (2013) 0.84
Questioning the utility of pooling samples in microarray experiments with cell lines. Int J Biol Markers (2006) 0.84
Hepcidin and ferritin blood level as noninvasive tools for predicting breast cancer. Ann Oncol (2013) 0.84
Inhibition of telomerase activity by a hammerhead ribozyme targeting the RNA component of telomerase in human melanoma cells. J Invest Dermatol (2000) 0.84
ALT-associated promyelocytic leukaemia body (APB) detection as a reproducible tool to assess alternative lengthening of telomere stability in liposarcomas. J Pathol (2008) 0.84
Prognostic significance of proliferative activity and ploidy in node-negative breast cancers. Ann Oncol (1993) 0.84
Novel insights into targeting ATP-binding cassette transporters for antitumor therapy. Curr Med Chem (2011) 0.84
Targeting DNA topoisomerase I with non-camptothecin poisons. Curr Med Chem (2012) 0.83
Cell growth inhibition, G2M cell cycle arrest and apoptosis induced by the imidazoacridinone C1311 in human tumour cell lines. Eur J Cancer (2001) 0.83
Biological characterisation of primary and metachronous lesions in breast cancer patients. Eur J Cancer (1992) 0.83
Preclinical and clinical evaluation of four gemcitabine plus carboplatin schedules as front-line treatment for stage IV non-small-cell lung cancer. Ann Oncol (2003) 0.83
Expression of apoptosis-related markers and clinical outcome in patients with advanced colorectal cancer. Br J Cancer (2001) 0.83
Purine salvage enzyme activities in normal and neoplastic human tissues. Cancer Biochem Biophys (1990) 0.83
Telomerase activity and telomere length in human ovarian cancer and melanoma cell lines: correlation with sensitivity to DNA damaging agents. Int J Oncol (2000) 0.83
Flexible modelling in survival analysis. Structuring biological complexity from the information provided by tumor markers. Int J Biol Markers (1999) 0.82
Cell kinetics as a predictive factor in node-positive breast cancer treated with adjuvant hormone therapy. J Clin Oncol (1993) 0.82
Cell proliferation in 3,800 node-negative breast cancers: consistency over time of biological and clinical information provided by 3H-thymidine labelling index. Int J Cancer (1997) 0.82
Quantitative immunohistochemical determination of cathepsin-D and its relation with other variables. Breast Cancer Res Treat (1993) 0.81
PF-03446962, a fully-human monoclonal antibody against transforming growth-factor β (TGFβ) receptor ALK1, in pre-treated patients with urothelial cancer: an open label, single-group, phase 2 trial. Invest New Drugs (2014) 0.81
Cell kinetics as a prognostic marker in locally advanced breast cancer. Cancer Treat Rep (1987) 0.80
Biological markers as indicators of pathological response to primary chemotherapy in oral-cavity cancers. Int J Cancer (1998) 0.80
Selective modulation of ER-beta by estradiol and xenoestrogens in human breast cancer cell lines. Cell Mol Life Sci (2003) 0.80
Development of a nucleotide precursor incorporation assay for testing drug sensitivity of human tumors. Recent Results Cancer Res (1984) 0.80
Modulation of cell cycle-related protein expression by sodium butyrate in human non-small cell lung cancer cell lines. Int J Cancer (2001) 0.80
Effect of melphalan and hyperthermia on cell cycle progression and cyclin B1 expression in human melanoma cells. Cell Prolif (1995) 0.80
In vitro activity of alkylating agents on human tumors as measured by a short-term antimetabolic assay. Tumori (1985) 0.80
Lack of a correlation between micronucleus formation and radiosensitivity in established and primary cultures of human tumours. Br J Cancer (1994) 0.80
Short-term tissue culture of human breast cancer: presence of estrogen receptors and 17 beta-estradiol stimulation of RNA synthesis. Cancer (1979) 0.80
Cholesteryl butyrate in solid lipid nanospheres as an alternative approach for butyric acid delivery. Anticancer Res (2000) 0.80
Activity of a trinuclear platinum complex in human ovarian cancer cell lines sensitive and resistant to cisplatin: cytotoxicity and induction and gene-specific repair of DNA lesions. Br J Cancer (2001) 0.80
Fluctuation of intratumor biological variables as a function of menstrual timing of surgery for breast cancer in premenopausal patients. Ann Oncol (2003) 0.79